Suppr超能文献

通过基因易位和g基因截短对重组水疱性口炎病毒-1型人类免疫缺陷病毒疫苗载体进行减毒,可降低神经毒性并增强小鼠的免疫原性。

Attenuation of recombinant vesicular stomatitis virus-human immunodeficiency virus type 1 vaccine vectors by gene translocations and g gene truncation reduces neurovirulence and enhances immunogenicity in mice.

作者信息

Cooper David, Wright Kevin J, Calderon Priscilla C, Guo Min, Nasar Farooq, Johnson J Erik, Coleman John W, Lee Margaret, Kotash Cheryl, Yurgelonis Irene, Natuk Robert J, Hendry R Michael, Udem Stephen A, Clarke David K

机构信息

Wyeth, 401 N. Middletown Rd., Pearl River, NY 10965, USA.

出版信息

J Virol. 2008 Jan;82(1):207-19. doi: 10.1128/JVI.01515-07. Epub 2007 Oct 17.

Abstract

Recombinant vesicular stomatitis virus (rVSV) has shown great potential as a new viral vector for vaccination. However, the prototypic rVSV vector described previously was found to be insufficiently attenuated for clinical evaluation when assessed for neurovirulence in nonhuman primates. Here, we describe the attenuation, neurovirulence, and immunogenicity of rVSV vectors expressing human immunodeficiency virus type 1 Gag. These rVSV vectors were attenuated by combinations of the following manipulations: N gene translocations (N4), G gene truncations (CT1 or CT9), noncytopathic M gene mutations (Mncp), and positioning of the gag gene into the first position of the viral genome (gag1). The resulting N4CT1-gag1, N4CT9-gag1, and MncpCT1-gag1 vectors demonstrated dramatically reduced neurovirulence in mice following direct intracranial inoculation. Surprisingly, in spite of a very high level of attenuation, the N4CT1-gag1 and N4CT9-gag1 vectors generated robust Gag-specific immune responses following intramuscular immunization that were equivalent to or greater than immune responses generated by the more virulent prototypic vectors. MncpCT1-gag1 also induced Gag-specific immune responses following intramuscular immunization that were equivalent to immune responses generated by the prototypic rVSV vector. Placement of the gag gene in the first position of the VSV genome was associated with increased in vitro expression of Gag protein, in vivo expression of Gag mRNA, and enhanced immunogenicity of the vector. These findings demonstrate that through directed manipulation of the rVSV genome, vectors that have reduced neurovirulence and enhanced immunogenicity can be made.

摘要

重组水泡性口炎病毒(rVSV)作为一种新型疫苗病毒载体已显示出巨大潜力。然而,先前描述的原型rVSV载体在非人灵长类动物中进行神经毒力评估时,发现其减毒程度不足以用于临床评估。在此,我们描述了表达1型人类免疫缺陷病毒Gag的rVSV载体的减毒、神经毒力和免疫原性。这些rVSV载体通过以下操作组合进行减毒:N基因易位(N4)、G基因截短(CT1或CT9)、非细胞病变性M基因突变(Mncp)以及将gag基因定位到病毒基因组的第一个位置(gag1)。直接颅内接种后,所得的N4CT1 - gag1、N4CT9 - gag1和MncpCT1 - gag1载体在小鼠中显示出神经毒力显著降低。令人惊讶的是,尽管减毒程度非常高,但N4CT1 - gag1和N4CT9 - gag1载体在肌肉内免疫后产生了强大的Gag特异性免疫反应,等同于或大于毒性更强的原型载体产生的免疫反应。MncpCT1 - gag1在肌肉内免疫后也诱导了等同于原型rVSV载体产生的Gag特异性免疫反应。将gag基因置于VSV基因组的第一个位置与Gag蛋白的体外表达增加、Gag mRNA的体内表达以及载体免疫原性增强相关。这些发现表明,通过对rVSV基因组的定向操作,可以构建出神经毒力降低且免疫原性增强的载体。

相似文献

3
Neurovirulence and immunogenicity of attenuated recombinant vesicular stomatitis viruses in nonhuman primates.
J Virol. 2014 Jun;88(12):6690-701. doi: 10.1128/JVI.03441-13. Epub 2014 Apr 2.
5
Vaccination With a Highly Attenuated Recombinant Vesicular Stomatitis Virus Vector Protects Against Challenge With a Lethal Dose of Ebola Virus.
J Infect Dis. 2015 Oct 1;212 Suppl 2(Suppl 2):S443-51. doi: 10.1093/infdis/jiv316. Epub 2015 Jun 24.
6
Recombinant vesicular stomatitis virus as an HIV-1 vaccine vector.
Springer Semin Immunopathol. 2006 Nov;28(3):239-53. doi: 10.1007/s00281-006-0042-3. Epub 2006 Sep 15.
7
Characterization of nonpathogenic, live, viral vaccine vectors inducing potent cellular immune responses.
J Virol. 2004 Sep;78(17):9317-24. doi: 10.1128/JVI.78.17.9317-9324.2004.

引用本文的文献

1
Preclinical Safety Assessment of the EBS-LASV Vaccine Candidate against Lassa Fever Virus.
Vaccines (Basel). 2024 Jul 30;12(8):858. doi: 10.3390/vaccines12080858.
2
Regulated control of virus replication by 4-hydroxytamoxifen-induced splicing.
Front Microbiol. 2023 Mar 13;14:1112580. doi: 10.3389/fmicb.2023.1112580. eCollection 2023.
3
Replicating-Competent VSV-Vectored Pseudotyped Viruses.
Adv Exp Med Biol. 2023;1407:329-348. doi: 10.1007/978-981-99-0113-5_18.
4
Utilization of Viral Vector Vaccines in Preparing for Future Pandemics.
Vaccines (Basel). 2022 Mar 12;10(3):436. doi: 10.3390/vaccines10030436.
5
A vesicular stomatitis virus-based prime-boost vaccination strategy induces potent and protective neutralizing antibodies against SARS-CoV-2.
PLoS Pathog. 2021 Dec 16;17(12):e1010092. doi: 10.1371/journal.ppat.1010092. eCollection 2021 Dec.
7
Rhabdoviruses as vectors for vaccines and therapeutics.
Curr Opin Virol. 2020 Oct;44:169-182. doi: 10.1016/j.coviro.2020.09.003. Epub 2020 Oct 29.
8
Oncolytic Virotherapy in Glioma Tumors.
Int J Mol Sci. 2020 Oct 14;21(20):7604. doi: 10.3390/ijms21207604.
10
Plant Viruses in Plant Molecular Pharming: Toward the Use of Enveloped Viruses.
Front Plant Sci. 2019 Jun 19;10:803. doi: 10.3389/fpls.2019.00803. eCollection 2019.

本文引用的文献

2
Use of viral vectors for the development of vaccines.
Expert Rev Vaccines. 2007 Apr;6(2):255-66. doi: 10.1586/14760584.6.2.255.
3
Quantitative multiplex assay for simultaneous detection of the Indiana serotype of vesicular stomatitis virus and HIV gag.
J Virol Methods. 2007 Jul;143(1):55-64. doi: 10.1016/j.jviromet.2007.02.007. Epub 2007 Mar 26.
4
HIV-1 vaccine development: progress and prospects.
Curr Infect Dis Rep. 2007 Jan;9(1):71-5. doi: 10.1007/s11908-007-0025-0.
6
Neurovirulence properties of recombinant vesicular stomatitis virus vectors in non-human primates.
Virology. 2007 Mar 30;360(1):36-49. doi: 10.1016/j.virol.2006.10.026. Epub 2006 Nov 13.
7
Recombinant vesicular stomatitis virus as an HIV-1 vaccine vector.
Springer Semin Immunopathol. 2006 Nov;28(3):239-53. doi: 10.1007/s00281-006-0042-3. Epub 2006 Sep 15.
8
Therapeutic efficacy of vesicular stomatitis virus-based E6 vaccination in rabbits.
Vaccine. 2007 Jan 8;25(4):751-62. doi: 10.1016/j.vaccine.2006.08.012. Epub 2006 Aug 22.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验